StemCell Therapy

Eli Lilly and Co. has played a key role in developing important medicines since its founding in 1876. Some of those drugs include penicillin, Prozac, Zyprexa and Humulin. Wochit

Eli Lilly and Company officials are asking the federal government to grant emergency approval to use a drug approved for rheumatoid arthritis to treat COVID-19, after a study showed it hastened recovery when used with another therapy.

The trial looked at the impact of adding baricitinib, marketed as Olumiant, to treatment with remdesivir, an antiviral. Patients who received both drugs recovered one day sooner than those who received remdesivir alone, the study of more than 1,000 hospitalized patients found.

Its quite a big outcome, said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines.

Those who received baricitinib along with remdesivir also required less clinical support while they were in the hospital and had better outcomes overall, Jonsson said.

While 24 hours may not seem like a dramatic difference, if hospitals are experiencing a surge in patients it can ease the strain on resources.

Eli Lilly officials said that while the results from the trial have not yet been peer-reviewed, they will be doing further analyses and expect to have more results soon.

Unlike remdesivir, which is an infusion, baricitinib is taken by mouth. Currently it is approved to treat rheumatoid arthritis. Jonsson said that if it was also approved for use in COVID-19, Lilly would be able to produce sufficient amounts for both conditions.

We are very confident that we are in a good position when it comes to supply, he said.

Rheumatoid arthritis patients take a 2-mg dose. Lilly plans to ask the FDA to approve a 4-mg dose for COVID-19. The drug currently comes with warnings about a risk of developing blood clots or infections.

Baricitinib is thought to help coronavirus patients by acting as an anti-inflammatory, Jonsson said. It is thought that the drug may lessen the effects of the so-called cytokine storm that the bodys own immune system may produce in response to the virus. It may also interfere with the viruss ability to reproduce, lowering the viral load.

Contact IndyStar reporter Shari Rudavsky at shari.rudavsky@indystar.com. Follow her on Facebook and on Twitter: @srudavsky.

Read or Share this story: https://www.indystar.com/story/news/health/2020/09/16/lilly-study-shows-rheumatoid-arthritis-drug-helps-treat-coronavirus/5803136002/

Read the original here:
Lilly study shows its drug for rheumatoid arthritis helps in coronavirus treatment - IndyStar

Dr Shashank Akerkar, consultant, rheumatology clarifies several doubts and misconceptions pertaining to hydroxychloroquine (HCQ) and highlights the safety and efficacy profile of HCQ. He mentions that in general, practicing rheumatologists prescribe HCQ without ordering a baseline ECG unless the patient has a history of cardiac disease. If the right dosage of HCQ is used for the right patient with no prior cardiac complication, it is not likely to cause cardiac adverse effects.

What is the role of HCQ in the management of COVID-19? Can it in any way cure the disease?

COVID-19 has multiple pathological features and therefore its management requires multiple drug therapies. Hydroxychloroquine (HCQ) alone cannot cure COVID-19 but it has been used in combination with other drugs for this purpose.

However, HCQ is not approved by the Drugs Controller General of India (DCGI) for the management of COVID-19. The Indian Council of Medical Research (ICMR), has recommended it as a prophylaxis (prevention) for COVID-19 (March 23, 2020) and for the treatment of mild and moderate cases of COVID-19 (June 13, 2020 ICMR management protocol).

In many studies, it has been found to decrease morbidity and mortality in COVID-19 patients. For example, in one retrospective observational study that included 3,451 patients from 33 hospitals in Italy, use of HCQ was associated with a 30 per cent lower risk of death in COVID-19 hospitalised patients.

In India, HCQ has shown promising outcomes as a prophylaxis for COVID-19 amongst healthcare workers. In a nation-wide case-control ICMR study with 751 health care workers, the intake of six or more doses of HCQ was linked to a >80 per cent reduction in the risk of COVID-19 infection.

For the last five decades, HCQ has been widely used for the management of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In in-vitro studies, HCQ has been found to possess antiviral activity against many viruses such as the rabies virus, poliovirus, HIV, hepatitis A virus, chikungunya virus, dengue virus, Zika virus and even SARS-CoV-2.

What are some of the common misconceptions about HCQ that have emerged since the COVID-19 pandemic?

During the pandemic, the use of HCQ has been linked to excessive cardiovascular adverse effects like QTc prolongation, arrhythmia and cardiovascular (CV) mortality. None of this has been conclusively proven through research.

In fact, for decades HCQ has been prescribed for those with RA and SLE, and CV adverse effects have been rare in these patients. A study with 1,537 RA patients on HCQ therapy, found no significant correlation between HCQ use and QT interval prolongation.

QTc prolongation is rarely seen with HCQ use and it is often a self-limiting event. QTc prolongation mostly occurs in the presence of several risk factors, such as high drug concentration and simultaneous exposure to QTc-prolonging drugs like azithromycin. It is possible that the QTc prolongation and arrhythmia observed in COVID-19 patients are cardiac manifestations of COVID-19 disease. Clinical evidence shows that patients with a severe case of COVID-19 are in an arrhythmogenic state with myocardial injury, hypoxia, renal insufficiency, and electrolyte disturbance. Use of antiviral drugs and azithromycin in COVID-19 patients has also been also linked to QTc prolongation.

In general, practicing rheumatologists prescribe HCQ without ordering a baseline ECG unless the patient has a history of cardiac disease. If the right dosage of HCQ is used for the right patient with no prior cardiac complication, it is not likely to cause cardiac adverse effects. However, an ECG (with estimation of QT interval) may be done before prescribing HCQ. The Indian Heart Rhythm Society recommends a baseline ECG to estimate the QTc interval in individuals receiving HCQ treatment. Thus, the rare CV risk linked to HCQ can be assessed proactively, which is why I believe the overall fear about serious CV adverse effects is unfounded and often exaggerated.

Of late, have you encountered any constraints when prescribing HCQ to patients?

There are no constraints in prescribing HCQ for patients with RA, SLE and type-2 diabetes. It has been approved by regulatory authorities such as the DCGI and US FDA for RA and SLE, and in addition to these indications, DCGI has approved it for the management of type 2 diabetes. HCQ has been used in these patients for a long period of time and it has a favourable safety profile.

Why do you believe that the controversy over HCQ is a myth?

Early in March, the WHO initiated a multinational trial of four untested drugs for COVID-19. HCQ was also a part of the trial. Then in May, Mehra et al published one multinational real-world analysis in The Lancet, in which they reported that HCQ treatment (alone or in combination with a macrolide) had no benefit on the in-hospital outcomes in patients with COVID-19. Instead, they concluded that HCQS increases mortality in patients with COVID-19, which led to the stopping of the WHO trial mentioned earlier.

Later on, Australian researchers found discrepancies in the mortality data for HCQ users. In response to this, The Lancet t published an expression of concern and retracted the article that had halted the HCQ trial. The members of the WHO trial committee recommend that there was no reason to modify the trial based on available mortality data. And on June 3, the WHO resumed the trial including the HCQs arm in patients with COVID-19. Most of the HCQS trials which were stopped earlier were also restarted.

What will be the consequences if HCQ is banned for use in COVID-19?

The COVID-19 pandemic is unprecedented and such a health crisis arises once in a century. The morbidity and mortality of COVID-19 is comparatively high. To control a viral pandemic of this kind, the following measures are generally required.

1) preventive healthcare measures e.g. social distancing, hand hygiene and wearing masks etc.

2) vaccination of the general population, when a vaccine is available

3) use of antiviral drugs

4) use of immunomodulatory drugs

5) repurposing of existing drugs when specific treatment is not available.

A vaccine that prevents COVID-19 would ideally have been the best measure. But it takes a long time to develop and test effective vaccines against RNA viruses with rapidly mutating strains. Similarly, it is extremely difficult to develop a specific antiviral drug in a short period of time.

Considering the high morbidity and mortality of COVID-19, newer antiviral drugs such as remdesivir, lopinavir/ritonavir have been repurposed to manage COVID-19 and existing drugs such as HCQ, azithromycin, other antiviral drugs, and dexamethasone have also been repurposed for the treatment of COVID-19. HCQ has been found effective for the treatment and prevention of COVID-19 disease.

No serious untoward effects have been observed with HCQ use for the last five decades that can cause the regulatory authorities to think about banning HCQ. Such a possibility is extremely remote as millions of RA and SLE patients are being successfully treated with HCQ without serious safety concerns.

(Note: These are not recommendations, to be considered as an opinion.)

Read more from the original source:
FAQs on HCQ use in rheumatoid arthritis and other conditions - Express Healthcare

One-and-a-half million people in the United States suffer from rheumatoid arthritis (RA). In fact, The Arthritis Foundation estimates that three times as many women as men have the disease and it affects individuals of all ages, but primarily women ages 30 to 60.

Commonly affecting the hands and feet of the body, RA is considered an autoimmune disease, where the body attacks joints, leading to inflammation and pain as well as a loss of motion. With a diagnosis comes a rapidly-changing lifestyle, often causing activities and hobbies that were once loved and now off-limits.

Through stories on the National Rheumatoid Arthritis Society website, many individuals have shared that arthritis has caused a dramatic lifestyle change thats often accompanied by depression and anxiety. But that doesnt have to be the case.

With patients young and old experiencing the debilitating effects of rheumatoid arthritis, individuals like Pearl Schomburg are advocating for doctors to mention the effects of cannabis in office. Pearl explained to Newshub, Cannabis balm was the first thing I discovered and was shocked by how well it worked.

RELATED: Theres No Known Cure For Arthritis, But Marijuana Works Wonders

The Arthritis Foundation recently shared information about CBD and marijuana on their website to educate patients around its use. Recognizing the potential to treat both inflammation and pain, they advise to always discuss CBD and cannabis with your care team and make sure to contact the manufacturer to see proof of a third-party analysis for purity.

Photo by rawpixel.com

In a 2018 study published in the journal CannabisandCannabinoid Research, researchers found that terpenoids, which exist in cannabis, offer anti-inflammatory properties, but didnt offer as much relief as purified CBD. Often used in chronic inflammation and for pain, purified CBD offered better relief in the study over other mixtures, including CBD.

Psoriasis, a condition where cells build on top of the skin and cause pain and redness, is often coupled with RA and offers treatment that can be very expensive. John S. from Minneapolis explained that his medicine came in the form of a shot billed to insurance at $60,000 each year creating a debilitating pattern of relying on pharmaceutical medicine that is often inaccessible. Would he explore CBD and cannabis? He explained, Its been on my mind; a year ago, I wouldnt have even thought about integrating CBD, now Im looking at reviews online. In fact, MedicalNewsToday cited 2016 research that suggested that cannabinoids offered benefits to individuals with psoriasis.

With the market ever-changing, not only are tinctures available, but patches as well. In 2016, a study found that placing CBD on the body in a topical fashion offered some relief for pain and inflammation over other methods. CBD comes in many forms, including:

As the cost of medicine continues to rise, CBD and cannabis offer a more affordable solution to many experiencing the effects of RA, inflammation and psoriasis.

RELATED: Young People Experience Arthritis Too And Cannabis Can Help

House of Cannabis, a new pot shop in Twisp, WA, is seeing a steady increase (about 52%) of customers coming in aged 50 and older. Mainly focused on pain relief, House of Cannabis has been both startled and empowered by the number of older adults coming in for the first time.

Arthritis is probably the most common issue people are dealing with in their hands, back and legs, shared Cindy Knutson, the retailers general manager and state-certified medical cannabis consultant. Were seeing a shift in mindsets and the market, Knutson continued, notating that adults who typically wouldnt have spoken about cannabis or CBD are now sharing with their friends.

Original post:
Whats Next For Rheumatoid Arthritis And Cannabis? - The Fresh Toast

Data Bridge Market Research has recently published the Global research Report Titled: Psoriatic Arthritis Treatment Market

The research and analysis conducted in Psoriatic Arthritis Treatment report help clients to predict investment in an emerging market, expansion of market share, or success of a new product with the help of global market research analysis. This report has been designed in such a way that it provides a very evident understanding of the business environment and Psoriatic Arthritis Treatment industry. Nevertheless, this global market research report unravels many business problems very quickly and easily. Due to high demand and the value of market research for the success of different sectors, Psoriatic Arthritis Treatment Market report is provided that covers many work areas.

Global psoriatic arthritistreatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned forecast period. Factors such as growing number of smokers, alcoholism and obesity are propelling the growth of psoriatic arthritistreatment market globally.

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-psoriatic-arthritis-treatment-market&utm_source=&kA

The Global Psoriatic Arthritis Treatment Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Psoriatic Arthritis Treatment market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Psoriatic Arthritis Treatment Market in each region. Various methodological tools are used to analyze the growth of the worldwide Psoriatic Arthritis Treatment market.

Prominent Key Players Covered in the report:

GlaxoSmithKline plc, Cumberland Pharmaceuticals Inc, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., Novartis AG, Alvogen, Bayer AG,Currax Pharmaceuticals LLC,Mylan N.V., Azurity Pharmaceuticals, Inc., Antares Pharma, Cumberland Pharmaceuticals Inc., Vintage Labs, Pfizer Inc., Samsung Biologics, Amgen Inc, Johnson & Johnson Services, Inc.

Regional Analysis Includes:

Scope of Report:

Psoriatic Arthritis Treatment MarketGlobal industry research report is a professional and in-depth study on the market size, growth, share, trends, as well as industry analysis. The report begins with an overview of the industrial chain structure and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companys profiles, besides, market price and channel features are covered in the report. Furthermore, market size, the revenue share of each segment and its sub-segments, as well as forecast figures are also covered in this report.

Important Features that are under offering & key highlights of the report:

Why choose us:

Moreover, the report gives production, consumption, sales, and other market forecasts. The document contains the details associate with sales channels, suppliers, traders, dealers, research findings and conclusion, etc for the Psoriatic Arthritis Treatment market. In-depth global market progress and outlook linked with the factors boosting the market are explained in the report.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-psoriatic-arthritis-treatment-market&utm_source=&KA

Key Questions Answered:

Table Of Contents

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

In conclusion, the Psoriatic Arthritis Treatment Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

For More Information or Query or Customization Before Buying, Click Here: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psoriatic-arthritis-treatment-market&utm_source=&KA

Request a customized copy of Psoriatic Arthritis Treatment Market report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA, or Asia Pacific.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Go here to read the rest:
Psoriatic Arthritis Treatment Market revenue to expand at significant CAGR through 2027 - The Daily Chronicle

Rheumatoid Arthritis Drugs Market Scenario 2020-2028:This detailed market study covers Rheumatoid Arthritis Drugs Market growth potentials which can assist the stakeholders to understand key trends and prospects in the Rheumatoid Arthritis Drugs market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global Rheumatoid Arthritis Drugs market

Rheumatoid Arthritis Drugs

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-65374?utm_source=DC/SA

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company

According to the report, the Rheumatoid Arthritis Drugs market report points out national and global business prospects and competitive conditions for Rheumatoid Arthritis Drugs. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Rheumatoid Arthritis Drugs. The Rheumatoid Arthritis Drugs market has been segmented as By Type of Molecule (Pharmaceuticals, Biopharmaceuticals), By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Analgesics) . Historical background for the demand of Rheumatoid Arthritis Drugs has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Rheumatoid Arthritis Drugs have also been established with potential gravity.

Regional segmentation and analysis to understand growth patterns: The market has been segmented in major regions to understand the global development and demand patterns of this market. By region, the Rheumatoid Arthritis Drugs market has been segmented in North America, Europe, Asia Pacific, Middle East & Africa, and South America. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-65374?utm_source=DC/SA

Europe region is dominated by Germany, the UK, France, Italy, and Spain. These countries also have a strong influence on the industrial sector resulting in sizeable demand for the Rheumatoid Arthritis Drugs market. Asia Pacific is estimated to register the highest CAGR by region during the forecast period. The presence of some of the high growth economies such as China and India is expected to propel the demand in this region. Besides, this region has witnessed strategic investments by major companies to increase their market presence. The Middle East and Eastern Europe are estimated to be other key regions for the Rheumatoid Arthritis Drugs market with a strong market potential during the forecast period. The rest of the World consisting of South America and Africa are estimated to be emerging markets during the forecast period.

This report provides: 1) An overview of the global market for Rheumatoid Arthritis Drugs market and related technologies.2) Analysis of global market trends, yearly estimates, and annual growth rate projections for compounds (CAGRs).3) Identification of new market opportunities and targeted consumer marketing strategies for the global Rheumatoid Arthritis Drugs market.4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-65374?utm_source=DC/SA

Objectives of this report: To estimate the market size for the Rheumatoid Arthritis Drugs market on a regional and global basis. To identify major segments in the Rheumatoid Arthritis Drugs market and evaluate their market shares and demand. To provide a competitive scenario for the Rheumatoid Arthritis Drugs market with major developments observed by key companies in the historic years. To evaluate key factors governing the dynamics of the Rheumatoid Arthritis Drugs market with their potential gravity during the forecast period.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

View post:
Rheumatoid Arthritis Drugs Market: Prospective Growth Trends & Incremental Opportunity Assessment till 2028 - The Daily Chronicle

Market Study Report LLC presents an extensive report on Rheumatoid Arthritis Therapeutics market that offers qualitative information about prevailing trends and a detailed analysis of the growth trajectory of this industry. It also includes a study of the historical data and detailed statistics that will help determine the future scope of the industry in terms of commercialization opportunities.

.

Request a sample Report of Rheumatoid Arthritis Therapeutics Market at:https://www.marketstudyreport.com/request-a-sample/2927518?utm_source=thedailychronicle.in&utm_medium=AN

The Rheumatoid Arthritis Therapeutics research report provides a detailed assessment of this business sphere. This report also estimates the market share and growth rate attained over the forecast period. The report unravels all the key aspects of Rheumatoid Arthritis Therapeutics market including revenue forecasts, industry size, and sales amassed with respected to each industry segment. The key growth drivers and the restraints of this industry vertical have also been elucidated in the report.

Understanding the Rheumatoid Arthritis Therapeutics market with respect to the regional landscape:

Ask for Discount on Rheumatoid Arthritis Therapeutics Market Report at:https://www.marketstudyreport.com/check-for-discount/2927518?utm_source=thedailychronicle.in&utm_medium=AN

Additional insights of the Rheumatoid Arthritis Therapeutics market report are listed below:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-rheumatoid-arthritis-therapeutics-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Animal Shelter Management Software Market 2020 by Company, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-animal-shelter-management-software-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global and China Student Management Systems Market 2020 by Company, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-and-china-student-management-systems-market-2020-by-company-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/military-vetronics-market-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2020-09-21?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Continue reading here:
Rheumatoid Arthritis Therapeutics Market Presents an Overall Analysis, Trends and Forecast to 2025 - The Daily Chronicle

It is worth mentioning this is highly beneficial in cases of arthritis. Further, glucosamine has been able to demonstrate its remarkable ability to lessen collagen breakdown.

(Newswire.net -- September 21, 2020) Orlando, FL -- Arthritis is undeniably a painful condition, and unfortunately, it affects millions and millions of people worldwide. Aside from pain, individuals with this disease also suffer from other symptoms like fatigue.

Experts have time and again warned that there are actually culprits behind fatigue in cases of arthritis. It may be due to depression, which actually goes hand in hand with the disease. The loss of muscle mass may also be a culprit.

It is worth noting that losing muscle tissue burdens the remaining muscles during body movements.

Inactivity is one of the common reasons behind the loss of muscle mass. However, there are those with severe inflammatory arthritis that also suffer from cachexia, which happens when there are decreases in muscle mass and increases in fatigue.

Some other medical conditions increases the odds of fatigue, such as lung disease, heart disease, diabetes, and inflammatory bowel disease. There are also other conditions not linked with arthritis found to result in fatigue.

These are thyroid disease, kidney or liver disease, and chronic fatigue syndrome. Arthritis is often managed through the use of certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

These medications are useful in temporarily easing pain and enhancing mobility. Individuals who are looking for safer pain relievers may take into account the use of supplements like glucosamine, which is a widely studied natural amino sugar.

Over decades, researchers have been carrying out studies to look into the beneficial effects of this remedy. It has been found that it works in enhancing the health and protection of the joint cartilage.

It is worth mentioning this is highly beneficial in cases of arthritis. Further, glucosamine has been able to demonstrate its remarkable ability to lessen collagen breakdown. In individuals with osteoarthritis, this remedy may be helpful in lessening inflammation.

This is due to the fact that inflammation is found to be one of the major culprits of joint cartilage breakdown.

There are many studies looking into the healing goodness of this remedy. Studies have time and again revealed that the use of this remedy worked in lessening pain as well as enhancing function among adults with osteoarthritis.

This therapeutic remedy has also been found helpful in improving overall symptoms, such as stiffness and pain.

Today, formulas like VitaBreeze Glucosamine are widely resorted to by individuals with this condition. While there are many formulas available in the global market today, this one from VitaBreeze is thought widely to be superior over others (www.amazon.com/Glucosamine-Chondroitin-Turmeric-Dietary-Supplement/dp/B00DUMO9X4).

VitaBreeze is a nutraceutical brand that manufactures high-quality natural supplements to help people live a healthy, enjoyable, and longer life. All of the companys products are manufactured in the United States using the finest-quality ingredients that have been carefully selected, tested, and crafted into the firms winning formulas. Visit http://www.VitaBreeze.com to learn more.

Continued here:
Health Authorities Warn About the Reasons Behind Fatigue in Arthritis - Newswire

The Canine Arthritis Treatment Market study offers an in-depth analysis of the current market trends influencing this business vertical. The study also includes market valuation, market size, revenue forecasts, geographical spectrum and SWOT Analysis of the industry. In addition, the report depicts key challenges and growth opportunities faced by the industry bigwigs, in consort with their product offerings and business strategies.

A collective analysis of Canine Arthritis Treatment Market offering an exhaustive study based on current trends influencing this vertical across various geographies has been provided in the report. Also, this research study estimates this space to accrue considerable income during the projected period, with the help of a plethora of driving forces that will boost the industry trends during the forecast duration. Snippets of these influences, in tandem with countless other dynamics relating to the Canine Arthritis Treatment Market, like the risks that are predominant across this industry along with the growth prospects existing in Canine Arthritis Treatment Market, have also been charted out in the report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2737

The report covers exhaustive analysis on:

Regional analysis includes

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2737

The report provides extensive data concerning the market share that each one of these companies presently gather throughout this business, followed by the market share that they are anticipated to acquire by the end of the predicted timeframe. Also, the report expounds on details relating to the goods manufactured by these firms, that would help new industry participants and major stakeholders work on their competition and portfolio strategies. In addition, their policymaking process is likely to get easier since the Canine Arthritis Treatment Market report also enumerates an idea of the trends in product prices and the revenue margins of all the major companies partaking in the industry share.

Queries that the Canine Arthritis Treatment Market report answers in respect of the regional landscape of the business domain:

Get Full Report Access athttps://www.xploremr.com/cart/2737/SL

Significant takeaways from the study:

The Canine Arthritis Treatment Market report hosts excess deliverables that may be highly advantageous. Say for instance, the report emphasizes information regarding market competition trends extremely essential data subject to contender intelligence and the current industry drifts that would enable shareholders to compete and take advantage of the biggest growth opportunities in the Canine Arthritis Treatment Market.

Another vital takeaway from the report can be accredited to the industry concentration rate that could help stakeholders to speculate on the existing sales dominance and the probable trends of the forthcoming years.

Additional deliverables mentioned in the report include details pertaining to the sales channels deployed by prominent sellers in order to retail their status in the industry, including direct and indirect marketing.

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

See the article here:
Canine Arthritis Treatment Market to Witness a Healthy YoY Growth during 2018 2028 - The Daily Chronicle

Given the debilitating impact of COVID-19 (Coronavirus) on the Psoriatic Arthritis Therapeutics market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Psoriatic Arthritis Therapeutics market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

The report provides both quantitative and qualitative information of global Psoriatic Arthritis Therapeutics market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Psoriatic Arthritis Therapeutics is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Psoriatic Arthritis Therapeutics market was valued at USD _ million/billion.

This research report based on Psoriatic Arthritis Therapeutics market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Psoriatic Arthritis Therapeutics market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Psoriatic Arthritis Therapeutics industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13729

Psoriatic Arthritis Therapeutics Market Overview:

The Research projects that the Psoriatic Arthritis Therapeutics market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Psoriatic Arthritis Therapeutics Market:

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13729

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13729

The Questions Answered by Psoriatic Arthritis Therapeutics Market Report:

And Many More.

See original here:
Psoriatic Arthritis Therapeutics Market To Witness A Considerable CAGR Growth Through The Forecast Period 2017 2025 - The Daily Chronicle

According to results of an observational study, nearly half of real-world patients developing a rheumatologic immune-related adverse event (irAE) while undergoing treatment with an immune checkpoint inhibitor (ICI) were able to continue ICI treatment without interruption. These findings were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.1

In this presentation, Karolina Benesova, MD, of the department of hematology, oncology, and rheumatology at University HospitalHeidelberg, Germany, described the rationale for, and characteristics of, a registry of real-world patients with cancer who exhibit symptoms of rheumatic disease.

With patient recruitment initiated at the University of Heidelberg in 2018, the MalheuR project (Malignancies and rheumatic diseases) was described as an open-label, nonrandomized, retro- and prospective, noninterventional observational study with a focus on gaining understanding of the inter-relationships between malignant and rheumatic diseases and facilitating the development of standardized guidelines to manage both of these disease processes.

Dr Benesova explained that the MalheuR project has 3 dimensions, each of which represents a possible context of coincidence between malignant and rheumatic diseases:

With 550 patients enrolled in the registry after 2 years, this presentation focused on the 77 patients in the TRheuMa arm. Of these patients, 65 were undergoing treatment with ICI therapy, and 38%, 33%, and 17% were classified as having a diagnosis of non-small cell lung cancer (NSCLC), melanoma, and other malignancy, respectively.

A key approach to facilitating a better understanding of underlying disease processes is the further classification of patients treated with ICI therapy according to the pattern of rheumatic disease that their irAEs resemble.

Thus far, 39% of patients have exhibited irAEs represented by an asymmetric spondyloarthritis/psoriatic arthritis-like pattern, 20% of patients have irAEs characterized by a symmetrical pattern that mostly involve small joints, such as rheumatoid arthritis, and 14% of patients had irAEs resembling polymyalgia rheumatic-like disease, such as symmetrical myalgia of the shoulder and hip girdle.

Also, a growing number of patients with preexisting [rheumatic disease] experience a flare of their disease as an irAE, reported Dr Benesova.

Regarding laboratory parameters, specific findings were reported to be rare, with the presence of autoantibodies mostly absent, although approximately three-quarters of patients had elevated C-reactive protein (CRP) levels. Of note, pathologic arthrosonographic findings were observed 49 of 51 patients evaluated with this method.

In reviewing a previously published therapeutic algorithm for rheumatic irAEs developed in collaboration with oncologists,2 Dr Benesova described how mild-to-moderate rheumatic irAEs, like tendinitis and arthritis, usually respond well to low-dose prednisolone up to 10 mg, NSAIDS, or combination of both.

She also noted that while oncologists usually discontinue ICIs at oral prednisolone levels above 10 mg, such treatment allows for continuation of ICI therapy.

From our experience, rheumatic irAEs respond better to low-dose prednisone than classical [rheumatological diseases], she commented.

The presence of more severe symptoms or organ manifestations typically necessitates high-dose oral prednisolone up to 1 mg/kg daily, and ICIs are withheld. Finally, life-threatening rheumatic irAEs such as severe myositis, while very rare, necessitate treatment with intravenous prednisolone up to 2 mg/kg daily and permanent discontinuation of ICI therapy.

Of the 65 patients receiving ICI therapy, rheumatic irAEs were sufficiently managed with steroids up to 10 mg daily with or without NSAIDS in 42%; ICI discontinuation was necessary in only 15% of patients.

Regarding oncologic outcomes for the patients with melanoma (25 individuals), a complete response (CR) was achieved in 48%, which was longstanding in most patients. For those with a diagnosis of NSCLC (29 individuals), no patient achieved a CR, but a partial response was observed in 69% of patients, with duration of response still under investigation.

In her concluding remarks, Dr Benesova stated that rheumatic irAEs are mostly not severe, well verifiable by imaging and CRP (seldom by autoantibodies), mostly well treatable, and associated with a better oncologic outcome.

Disclosure: Some of the authors of the study reported financial relationships with the pharmaceutical industry. For a full list of disclosures, please refer to the original abstract.

Read more of Cancer Therapy Advisors coverage of the ESMO Virtual Congress 2020 by visiting the conference page.

References

See the original post here:
Tracking Symptoms and Outcomes in Real-World Patients Exhibiting Rheumatic irAEs - Cancer Therapy Advisor

DetailsCategory: Small MoleculesPublished on Sunday, 20 September 2020 11:23Hits: 632

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine

INDIANAPOLIS, IN, USA I Septemer 18, 2020 I Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

This opinion marks the first step toward European regulatory approval for baricitinib (marketed as OLUMIANT) for patients with AD. If approved, baricitinib would become the first JAK inhibitor indicated to help treat patients with AD. The CHMP opinion is now referred for action to the European Commission, which grants approval in the European Union. A final decision is expected from the European Commission in the next one-two months.

"Due to the limited treatment options currently available for adult patients with AD, we're excited to further explore baricitinib's potential benefit for patients,"said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines. "At Lilly, we aspire to elevate treatment standards for patients with dermatologic conditions. Today's CHMP opinion brings us closer to providing a new medicine for adults living with AD in Europe."

The positive opinion was based on Lilly's Phase 3 BREEZE-AD clinical development program for baricitinib evaluating the medicine's potential to treat AD including BREEZE-AD1 and BREEZE-AD2, monotherapy studies investigating the efficacy and safety of baricitinib in moderate to severe AD patients; BREEZE-AD4, a study evaluating the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD who have failed or who are intolerant to, or have contraindications to cyclosporine; and BREEZE-AD7, a study evaluating the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD.

"Patients living with AD face difficulties on a daily basis, and this CHMP opinion marks an important milestone in providing adult AD patients with a new potential treatment option," said Prof. Thomas Bieber, M.D., Ph.D., M.D.R.A., Professor of Dermatology and Allergy, University Hospital in Bonn, Germany.

OLUMIANT is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis (RA).

Lilly has exclusive worldwide development and commercialization rights for baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases under a license and collaboration agreement with Incyte.

Information on the previously approved EU OLUMIANT indication (Rheumatoid Arthritis) can be found here.

Indication and Usage for OLUMIANT (baricitinib) tablets (inthe United States) for RA patients

OLUMIANT(baricitinib) 2-mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.Limitation of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

About OLUMIANT

OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. for the treatment of adults with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the U.S. for patients with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.1There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.2OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.1OLUMIANT is approved in more than 70 countries. OLUMIANT is developed by Lilly under license from Incyte Corporation.

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.3 AD is a heterogeneous disease both biologically and clinically, but may be characterized by chronic symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.4,5 AD affects approximately one-three percent of adults worldwide.6

Moderate to severe AD is characterized by intense itching, resulting in visibly damaged skin.7 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.8

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

AboutEli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us atlilly.comandlilly.com/newsroom.

About IncyteIncyteis aWilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information onIncyte, please visit Incyte.com and follow @Incyte.

1 Olumiant Prescribing Information, 2020.2 Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.3 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.4Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.5 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.6 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.7 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.8 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

Refer to:Kristen Porter Basu; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-447-2199 (media)Kevin Hern; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-277-1838 (investors)Catalina Loveman; This email address is being protected from spambots. You need JavaScript enabled to view it.; +1-302-498-6171 (Incyte media)Michael Booth, DPhil; This email address is being protected from spambots. You need JavaScript enabled to view it.; +1-302-498-5914 (Incyte investors)

SOURCE: Eli Lilly

Continued here:
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis | Small Molecules | News...

Objectives:Osteoarticular infections are infrequent in pediatric patients, although their incidence seems to be increasing. They usually affect children younger than 5 years and tend to localize in the lower limbs. Because of their nonspecific symptoms, especially at onset, a timely diagnosis is difficult to achieve, with the subsequent risk of a delay in treatment. We hereby report the management of osteoarticular infections in our pediatric emergency department.

Methods:This is a retrospective descriptive study of patients diagnosed with osteoarticular upper limb infection in the pediatric emergency department of a tertiary hospital from January 2011 to December 2016.

Results:From an initial global sample of 170 patients diagnosed with osteomyelitis or septic arthritis at any location at the pediatric emergency department, 32 children (18.82%) with upper limb involvement were included in the study. Of them, 22 were male and the mean age at diagnosis was 14.5 months (interquartile range, 2-106). Eighteen patients (56%) were diagnosed with septic arthritis, and 14 (44%) had a diagnosis of osteomyelitis.The most frequent symptom was pain (50%). More than one third of patients (11) had received a different diagnosis in a previous hospital visit. A traumatic etiology was suspected in 7 cases (21%).Regarding acute phase reactants, the mean value for C-reactive protein was 21.3 mg/L, and erythrocyte sedimentation rate was elevated in 27 cases (84%). In 28 patients, blood cultures were obtained, 24 of which came back negative. All children received antibiotic treatment and achieved a full recovery.

Conclusions:One third of patients were misdiagnosed at the first consultation, which stresses the importance of a high clinical suspicion to avoid delays in diagnosis and treatment of osteoarticular infections. This study also shows a lower mean age of children with upper limb infection as compared with those with lower limb infection. All patients recovered fully with oral antibiotics.

Read the original here:
Characteristics of Upper Limb Osteoarticular Infections at the Emergency Department of a Tertiary University Hospital in Spain - DocWire News

KIRKLAND, QC, Sept. 15, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that Health Canada has approved BRENZYS, a TNF-inhibitor, for four new indications:

BRENZYS is a type of protein called a tumour necrosis factor (TNF) blocker that blocks the action of a substance the body makes called TNF-alpha. TNF-alpha is made by the body's immune system.5 People with immune diseases like JIA, PsA and PsO have too much TNF-alpha in their bodies, which can cause inflammation and lead to painful, swollen joints and raise thick, red, scaly patches ("psoriatic skin lesions") that can appear anywhere on the body.6 It can reduce the amount of TNF in the body to normal levels, helping to treat joint damage and psoriatic skin conditions. 7

An estimated one million Canadians live with psoriasis,8 and between 10 and 30% of these patients will develop psoriatic arthritis.9 Plaque Psoriasis is an inflammatory disease that affects the skin and can cause psoriatic skin lesions that can appear anywhere on the body.10 About 80% to 90% of people with psoriasis have plaque psoriasis, the most common type of psoriasis.11 PsA is usually seen in patients with PsO and affects both the joints and the skin.12 JIA is an inflammatory disease that affects the joints in the body and is the most common type of arthritis in children under the age of 16.13 Approximately 10,000 children and teens live with arthritis in Canada.14

"Merck is committed to providing Canadians with more therapeutic choices for patients and their treaters," says AnnA Van Acker, President, Merck Canada. "BRENZYS adds to Merck's portfolio of treatments for dermatological and inflammatory immune diseases and can help improve quality of life for patients living with psoriasis, psoriatic arthritis or juvenile idiopathic arthritis, as well as rheumatoid arthritis and ankylosing spondylitis."

About BRENZYS

BRENZYS is a biosimilar biologic drug (biosimilar)15 and authorized based on its similarity to ENBREL, which is already approved for use for PsO, PsA and JIA in Canada.16 A biosimilar is a biologic drug that is highly similar to a biologic drug already authorized for sale.17 Biosimilars are assessed and approved by Health Canada against the same meticulous standards used to ensure the quality, efficacy and safety of all other biologic drugs.18 Biosimilars provide patients more treatment options to help manage their disease and symptoms.

In addition to its use for the treatment of JIA, PsO and PsA, BRENZYS was first approved by Health Canada in 2016 for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults and ankylosing spondylitis (AS).19 It is administered by an injection under the skin and should be used under the guidance and supervision of a physician.20

Clinical efficacy and safety studies have been conducted in patients with rheumatoid arthritis to demonstrate clinical comparability between BRENZYS and ENBREL. The extrapolation of these data to support uses of BRENZYS in ankylosing spondylitis is based on the demonstrated comparability, in terms of product quality, non-clinical, human pharmacokinetic and clinical characteristics. Randomized clinical trials have not been conducted to compare BRENZYS to Enbrel in patients with psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis and pediatric psoriasis.21

The most common expected adverse reactions with BRENZYS are infections, injection site reactions and headaches. It should not be administered to patients with or at risk of sepsis. BRENZYS contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections including tuberculosis and infections caused by bacteria, viruses or fungi that have spread throughout their body. The Boxed Warning also notes that malignancies, sometimes fatal, have been reported in children and teenage patients who started using TNF-blocking agents, including etanercept, at less than 18 years of age.22

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling $89 million in 2019 and more than $1.3 billion since 2000. Based in Kirkland, Qubec, Merck employs approximately 650 people across the country. For more information about our operations in Canada, visit http://www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2017 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Please see the product monograph for BRENZYS (etanercept injection) at:

https://www.merck.ca/static/pdf/BRENZYS-PM_E.pdf

References

1 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

2 Psoriasis. Canadian Dermatology Foundation. 2020.

3 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

4 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

5 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

6 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

7 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

8 Psoriasis. Canadian Dermatology Foundation. 2020.

9 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

10 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

11 Symptoms. Canadian Association of Psoriasis Patients. 2014. canadianpsoriasis.ca/index.php/en/psoriasis/81-english/psoriasis/94-symptoms#:~:text=About%2080%25%20to%2090%25%20of,with%20silvery%20scales%20on%20top

12 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

13 https://www.mayoclinic.org/diseases-conditions/juvenile-idiopathic-arthritis/symptoms-causes/syc-20374082

14 6 facts about Juvenile Idiopathic Arthritis. Montreal Children's Hospital. 2020. https://www.thechildren.com/health-info/conditions-and-illnesses/6-facts-about-juvenile-idiopathic-arthritis

15 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

16 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

17 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

18 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

19 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

20 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

21 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

22 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

SOURCE Merck

Company Codes: NYSE:MRK

View original post here:
BRENZYS (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis - BioSpace

Theres no right way to practice self-care. It looks different for all of usultimately, good self-care consists of whatever helps you feel cared for. That's true for psoriatic arthritis self-care tips too. For people with psoriatic arthritis, an autoimmune condition that causes psoriasis symptoms plus issues like joint pain, stiffness, and swelling, self-care can be a huge help in managing the condition.

For people with arthritis, every day needs to be a bit of a self-care day, because you have to think of yourself before you think of anything else, Tanya G., 42, who was diagnosed 11 years ago but has had symptoms of psoriatic arthritis most of her life, tells SELF. Focusing on little things that can make your life easierlike having the right tools at your desk, or a talk-to-text app that you can use to email when your hands are flaredis self-care. Learning how to take things slowly and listening to your body is also self-care, says Annelyse A., 25, who creates artwork advocating for chronic illness on her Instagram account, Resting Itch Face. Surrounding yourself with people who care and support you? Also self-care.

Self-care simply boils down to taking care of yourself, says Tanya, sometimes in the most basic ways, and on an ongoing basis: Self-care is an everyday thing.

Here, Tanya, Annelyse, and Nitika C., 39, founder and CEO of Chronicon, a platform dedicated to elevating the lives of people with chronic illness, share the self-care practices and tips that have helped them live better with psoriatic arthritis.

You have to know what self-care means for you, says Tanya. For me, that means being prepared for bad days. Bad days will happen; theyre not going to magically go away. So what is going to be in my house that is going to support me on a bad day? For Tanya, this means having a few things on hand: bath bombs, a good book on her Kindle, and medication she can use during a serious flare. It means thinking ahead and doing laundry on a good day so her compression socks are clean and ready when she needs them. And, of course, it also means having her favorite comfort foods, like chocolate, on hand.

When I was really at my sickest in my 20s, I think the biggest thing that helped me was mindfulness, Nitika tells SELF. I didnt grow up knowing about it, but it really changed me. It made me feel like I could really help myself feel better on the inside, which I saw helped how I was feeling on the outside. Nitika says she noticed her stress levels go down when she learned how to stay present instead of letting the pain take over. Tanya also meditatesshe swears by the Calm app, specifically a training program the app has for pain management. I do it probably at least once a month to remember the steps for how to breathe through pain, she says.

While that laughter is the best medicine doesnt necessarily apply when it comes to chronic pain, it can still make a difference in how youre coping. Ive always known that friends and laughter were incredibly important, Nikita says. When she was younger and unable to get out of the house easily, she would call a friend to just talk. Not about psoriatic arthritis or the pain she was in, but just 20-something things like a cute guy or a weird dream or something that happened on a TV show. I remember that being so helpful. And even in times when that wasn't enough because maybe I was in so much pain or had a really big flare-up, I started getting into the habit of looking at funny videos online, like Carpool Karaoke, she adds. Its stupid and fun and makes me so happy, and its free.

For Tanya, self-care means making sure to surround herself with people who know that she may have to cancel plans and wont judge her or get angry at her for it. On the flip side, that also means distancing herself from people who just dont get itor rather, those who dont even attempt to understand. There are some people who don't get it who want to get it and say hurtful things because they just don't get it but want to be there for you. And then there are people who just think youre faking, and those are the people you have to distance yourself from, Tanya says.

Go here to read the rest:
9 Psoriatic Arthritis Self-Care Tips for Anyone With the Condition - Self

Arthritis is a common condition among dogs. It causes a lot of pain, and no pet parent wants their cuddle buddy to suffer! Read on to know how you can help your pooch cope with arthritis and its symptoms.

Arthritis in dogs can cause pain in the joints and affect dogs as they age. The most common type of arthritis that affects dogs is osteoarthritis, which usually affects seniors and large breeds. It is the inflammation of the joints caused by the deterioration of cartilage. Common symptoms of arthritis include limping, difficulty in moving, spinal issues, irritability, and tiredness. Some of the most common breeds that get affected by the problem include Labradors, Retrievers, German Shephard and Rottweilers.

Watching your furry friend suffering will definitely make you upset, and you might look for ways to curb the disease or decrease the pain. Well, there is no cure for the disease, but there are ways that can help to improve its symptoms. As a pet parent, you must help your canine to cope with the painful condition.

1- Arthritis is a common condition that affects overweight dogs. Helping them lose weight might decrease the pain and improve their symptoms.

2- Make them do gentle, controlled and low impact exercises that will keep them moving. It will help relieve the pain.

3-You can also invest in ramps to help your dog climb up the stairs, on the bed, stairs, or cars.

4-Regular massage will also help your pooch feel better. It will improve circulation, help them relax, lower blood pressure and reduce stress. You can gently massage your dogs joints, or seek professional help.

5- Invest in an orthopaedic dog bed that will support your quadrupeds joints and bones and help them relax.

6- Heating pads are another option that can help provide some relief. It will promote muscle relaxation, stimulate acupuncture points, and heal injuries.

ALSO READ:Want to know about your personality? Your pets can tell it all

x Your comment has been submitted to the moderation queue

Here is the original post:
Arthritis in Dogs: Heres how to help your canine cope with it - PINKVILLA

In her weekly column, Bradford West Gwillimbury licensed nutritionist Nonie De Long shares a few herbs you need in your medicine cabinet if you live with arthritis

Dear Nutritionist,

I suffer from arthritis and have to have a lot of medication for pain. I take daily NSAIDs and Im worried. I get horrible constipation and stomach pain and I notice the joint pain has started to get resistant. Ive had to go higher in my dose, which worries me. My rheumatoid arthritis started fiveyears ago. I was told it only gets progressively worse. I know theres no known cure but would you know of any safe and natural treatment that can help with the pain so I could reduce the amount of NSAIDs I take? Thank you for your column!

Thank you!Melaena from Barrie

Dear Malaena,

I love these difficult questions, keep them coming!

You are going to be on cloud 9, Malaena, because I know holistic therapies that both help with the pain of RH arthritis and ones that help manage it long-term. This is because I used to suffer from it. But not anymore.

You see, when I was 19 I was diagnosed with it. I had gotten mononucleosis from working at a cafe and handling all the dishware. When my immune system was taken out with mono I developed painful swelling in all my joints. I mean every joint - even my toes! My knees were at least 3x their normal size! I was at first diagnosed with water on the knee then had tests for rheumatoid factor (RF) and was diagnosed with migratory rheumatoid arthritis. They said it was migratory because after the initial flare up it moved around from joint to joint, often taking out several at once.

I was so ceased up I had to manually unlock my joints after sleeping because they would lock up in the position I had been in. It was excruciating. Ladies, think of the pain of labour and multiply that by 10! Its unbelievable how painful it is! Once I got moving I had to crawl to the bath - probably 3x a day - to soak in hot water. It was the only thing that gave me any relief.

All I could do was eat boiled noodles, drink hot chocolate, crush tylenol 3, bathe, and sleep. I moved like a zombie and a friend who saw me during that time commented that I looked like I had aged 30 years.

Fast forward to today and I rarely have a flare up and know exactly how to treat it if I do. But the solution came in increments over the years. Let me explain.

First, let me back up. During the flare up I had a manual car and couldnt drive because my knees couldnt handle it. This was before cell phones so I didnt have one of those either. And I had lost my job so I didnt have a landline either. I lived in the country and my then partner left. So I eventually ran out of food and hot chocolate. When I did I was forced to water fast. I now know water fasting is extremely beneficial for overcoming inflammation but I didnt know that then. I just knew that spontaneously started to get better. Within threedays of no food (toxins) I was feeling much much improved. Enough to drive and stop the T3. Once I did that, I never got so bad again.

But every year when I returned to school and rather frequently after parties the RA would flare up - sometimes for days and sometimes for months. It mostly affected my knees but also my elbows and shoulders and every time I had to wake to ceased joints I would get that familiar terror... wondering if it was coming back again. I lived in fear. Doctors and specialists could not explain the coming and going symptoms.

Then my stepmother made a discovery.

My father had had a triple bypass and had to switch to decaf for his recovery. Because of that she switched, too. She reported to me that her arthritis was much improved. Did I want to try it for mine? Well, it was easy enough to do so I switched to decaf all the time. Immediately I got about an 80 per centimprovement. So I ditched the caffeine altogether for a couple weeks and the RA went away entirely. I was flabbergasted. Everything started to make sense.

When I returned to school or went to functions I invariably drank coffee that I would not drink at home. Or eat a little chocolate something. I didnt have these in my home. I drank decaf at home because I knew the caffeine made me jittery. So when I drank regular coffee at school or functions I would get a flare up. I also realized why it got so bad with my migraines. My migraine medicine has caffeine in it. Guess what else does? T3s.

I had been living on hot chocolate and T3s when I had my worst flare up!

Today I have to be careful how much caffeine I have. But it took me years to be able to tolerate it at all. I had to work on my liver and remove low grade food intolerances from my diet. Still, if I overdo caffeine, dairy, and wheat I am down for a couple days. You could say those are my kryptonite.

Every person Ive treated for RA has serious underlying food intolerances and is sensitive to some degree to alcohol and caffeine. They usually also have some issues with their blood and digestion. Aside from telling you to switch to swiss water decaf and throw out the teas and chocolate immediately, I want you to avoid all alcohol and talk to your doctor about replacing any medications that have caffeine for a trial to see if it benefits you. I suggest you get food intolerance testing by a professional and figure out which foods trigger you. This is essential in the long run.

Next I suggest a few herbs to help with pain relief. NSAIDs are particularly damaging not only to the lining of the stomach and digestive system but to the gut biome, and this causes an increase in inflammation over time! That is not what we want.

Turmeric and the curcumin from it are both extremely beneficial in helping joint pain. They thin the blood, though, so a licensed physician needs to supervise use if you are taking blood thinners. The good news is it can work just like low dose aspirin without the side effects. But again, do not make changes without talking to a doctor to oversee this if you take meds for your blood. You can get this supplement in capsule form and you can add powdered turmeric to your food. Most potent may be the liposomal form, but it would need to be consumed with food. You can also use the root, which looks like a bright orangey yellow ginger - to fresh juices for added benefit.

The reason NSAIDs damage the stomach lining is they down regulate prostaglandins - of which some cause pain and some protect against pain and protect tissues like the stomach lining. We can effectively increase the beneficial prostaglandins by adding quality krill or cod liver or omega 3 fish oil into the diet as a supplement in therapeutic quantities (again taken with meals) and adding sardines and salmon (with skin and bones) into the weekly diet. You would be amazed how many cool recipes there are for sardines and canned salmon on the internet. Do a search and try something new!

In addition, using herbs to help your liver work better helps address this issue at the root. I use milk thistle, dandelion, and alpha lipoic acid in high doses with custom herbal tinctures for clients with these issues. Professional supervision is best for any high dose of supplements for any length of time.

I also recommend a liquid diet to take strain off of the digestive system and ensure all nutrients are being absorbed optimally until the bodys inflammation is under control. Bone broth is particularly soothing to a weak digestive system. I also recommend smoothies with quality protein and collagen peptides to help nourish without producing inflammation. This has been very effective in a number of clients in reducing pain.

Another remedy for pain that is incredible and simple is capsaicin cream. Its made from the active ingredient in chilli peppers and helps reduce the transmission of pain signals in the nerves. It can be really helpful for rubbing on the site of pain and is very safe - as long as you use gloves to apply it and dont rub your eyes after!

Lastly, homeopathics that fit your specific situation are essential if you want to turn the problem around permanently. But homeopathic remedies applied without knowledgeable dietary intervention do not produce the same results in clients, in my experience. Nutrition is the foundation of the inflammatory response in the body.

I hope this helps your pain, Malaena, and invite you to reach out to address the arthritis more deeply together.

As always, if you have your own health/nutrition questions, dont hesitate to send me an email at nonienutritionista@gmail.com. Readers can find out more about my work and sign up for my newsletter at hopenotdope.ca.

Namaste!Nonie Nutritionista

See the original post here:
If you have arthritis, here are some ideas that could help - BradfordToday

Patients with lifelong psoriatic arthritis are required to undergo treatments for prolonged periods of time. Furthermore, the higher burden of co-morbidities in the elderly population has the potential of complicating treatment course.

A new study presented at the Clinical Congress of Rheumatology (CRR) East 2020 demonstrated that treatment with ustekinumab resulted in similar efficacy and safety profiles for both age populations.

Ustekinumab specifically targets the shared p40 subunit of Interleukin (IL)-12 and IL-23. The treatment is indicated for adult patients with active psoriatic arthritis.

A team led by Elke Theander, MD, PhD, Medical Advisor of Rheumatology, Janssen Pharmaceutica, conducted a post-hoc analysis of the PsABio Study with a specific focus on comparing treatment outcomes in patients aged <60 (n = 336) and 60 (n = 102) years.

The investigators in the original study had recruited 930 patients and assigned about half to receive ustekinumab as 1st, 2nd, or 3rd line of treatment.

They then measured effectiveness using components of the American College of Rheumatology (ACR) response criteria in addition to the clinical disease activity index for psoriatic arthritis (cDAPSA) and minimal disease activity (MDA).

In the post-hoc analysis, reported mean age within the older population was 67.3 years; in the younger population, mean age was 46.1.

As noted by Theander and colleagues, both groups had similar baseline characteristics.

However, the older population had a longer psoriatic arthritis disease duration as well as a higher proportion with a history of cardiovascular disease and corticosteroid use.

Following 6 months of treatment with ustekinumab, the two subpopulations reported similar changes from baseline in components of the ACR response criteria.

Additionally, 52.2% of patients <60 years achieved cDAPSA low disease or remissioncompared with 42.9% in the 60 years group.

Mean cDAPSA was -14.4 (95% CI, -16.5 to -12.2) for the younger patients and -12.6 (95% CI, -16.1 to -9.1) for the older patients.

Furthermore, 30.0% and 20.3% of the younger and older populations, respectively, achieved MDA.

Up to 18.5% of patients <60 years experienced 1 adverse eventsversus 20.0% percent in those 60 years.

Other safety measures1 serious adverse events and withdrawal of treatment due to adverse eventswere similarly comparable between the groups.

In a real-world setting, no clinically meaningful differences were observed in the effectiveness and safety of ustekinumab treatment in PsA patients 60 years or older compared with those younger than 60, Theander and team wrote.

The study, "Effectiveness and Safety of Ustekinumab in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study: A Post-hoc Analysis Comparing Elderly to Younger Patients," was presented at CCR East 2020.

Read the original here:
Ustekinumab Safe and Efficacious in Young and Elderly Patients with Psoriatic Arthritis - MD Magazine

Arthritis is a general term for more than 100 types of joint pain or joint disease. However, osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. Common arthritis joint symptoms include swelling, pain, stiffness and decreased range of motion.

These symptoms can greatly diminish a person's quality of life by making even simple tasks trying.

Unfortunately, there's no cure for arthritis, but there are many treatments that can help to alleviate symptoms.

Research has found a number of natural remedies that reduce the inflammation associated with arthritis.

Stinging nettle, which can be processed into supplements, dried, freeze-dried or cooked, appears to boast anti-inflammatory properties.

READ MORE:Best supplements for arthritis: The top three supplements to help ease painful joints

Stinging nettle packs a variety of compounds that may reduce inflammation, research suggests.

In animal and test-tube studies, stinging nettle reduced levels of multiple inflammatory hormones by interfering with their production.

In human studies, applying a stinging nettle cream or consuming stinging nettle products appeared to relieve inflammatory conditions, such as arthritis.

For instance, in one 27-person study, applying a stinging nettle cream onto arthritis-affected areas significantly reduced pain, compared to placebo treatment.

DON'T MISSBed bugs: The three different warning smells indicating you may have an infestation[INSIGHT]Hair loss treatment - Dr Sara explains the best type of shampoo to stimulate hair growth[ADVICE]Bowel cancer: Smelly warning sign which could indicate early diagnosis of deadly condition[INSIGHT]

In another study, taking a supplement that contained stinging nettle extract significantly reduced arthritis pain.

Additionally, participants felt they could reduce their dose of anti-inflammatory pain relievers because of this capsule.

If your arthritis is painful, you may not feel like exercising. However, being active can help reduce and prevent pain.

According to the NHS, regular exercise can also:

A growing body of research supports the benefit of aerobic and strengthening exercise in alleviating arthritis, according to a literature review.

It suggested that the intensity level of the aerobic exercise should be moderate to hard and exercise be performed three times weekly for a duration of 30 to 60 minutes.

Any type of exercise which makes you breathe deeper and faster can be aerobic.

Examples of low-impact aerobic exercises that are easier on your joints include walking, bicycling and swimming.

Exercise also aids weight loss, which is crucial for managing arthritis symptoms.

The NHS explains: "Too much weight places excess pressure on the joints in your hips, knees, ankles and feet, leading to increased pain and mobility problems."

To help you maintain a healthy weight and alleviate your arthritis symptoms, it's very important to eat a healthy, balanced diet, says the health body.

Your diet should consist of a variety of foods from all five food groups.

These are:

See the rest here:
Arthritis treatment: Apply this herbal cream to significantly reduce pain - Express

A new study presented at the 14th Annual North American Young Rheumatology Investigator Forum (NYRIF 2020) found an association between seropositive rheumatoid factor (RF) or the presence of anti-cyclic citrullinated antibodies (ACPA) and an increased prevalence of interstitial lung disease (ILD) among patients with rheumatoid arthritis.

The retrospective case-control review, led by Samarth Mathapathi, MD, Resident at Scripps Green Hospital, examined various combinations of RF and ACPA serotypes among patients in order to determine associations with ILD prevalence.Furthermore, they compared selected outcomes to see whether seropositivity can help predict the course of rheumatoid arthritis ILD.

Mathapathi and team assessed a total of 2084 adult patients with rheumatoid arthritis with and without ILD. Of the total, 82 had ILD, and 2002 did not.

They excluded patients with other rheumatologic or pulmonary conditions.

Furthermore, the team defined RF positive (RF (+)) as RF >15 IU/mL, and ACPA positive (ACPA (+)) as ACPA >6 IU/mL.

In their analysis, patients were divided into groups according to RF and ACPA status. Then they compared ILD prevalence, pulmonary function tests, progression of CT/chest X-ray, average pulmonary artery pressures, home oxygen dependency, all-cause mortality, and hospitalization for respiratory failures rates among the cohorts.

Thus, the investigators noted that prevalence of ILD was 6.3% and 5.2% in the RF (+) / ACPA (+) and RF (+) / ACPA (-) groups, respectively (P = .534).

Prevalence was 3.9% in the RF (-) / ACPA (+) group and 1.3% in the RF (-) / ACPA (-) group (P < 0.05).

Furthermore, the mean titers of ACPA and RF in all ILD cohorts were 397 IU/mL and 484 IU/mL, respectively.

For those without ILD, means titers were 235 IU/mL for RF and 250 IU/mL for ACPA.

When compared across all the ILD groups, the outcomes among all other aforementioned measures were not significantly difference (P > .05).

The only notable exception was progression on imagingwhich was significant only in the RF (+) / ACPA (-) group. Thus, the investigators believed that this finding suggests a potential difference in disease course or other confounding underlying conditions.

Positive and higher titers of ACPA or RF may help predict development of RA-ILD but may not help prognosticate disease course, they concluded.

They acknowledged that larger and prospective studies would be necessary to confirm and validate their findings.

Concomitant rheumatoid arthritis and ILD has a varying prevalence, ranging from 3.2-6.0 cases per 100,000. The median survival rate is 7.8 years.Notable risk factors include age, female sex, and severity of rheumatoid arthritis.

The study, Comparison of Selected Outcomes in Seropositive vs. Seronegative Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD), was presented at NYRIF 2020.

Read the rest here:
Seropositive Antibodies Linked with Prevalence of Rheumatoid Arthritis-Associated ILD. - MD Magazine

'For people with arthritis, it is all about accessibility and comfort,' says Michael Kulava, who lives with rheumatoid arthritis himself and will be taking part in New York Fashion Week

A world-class fashion designer,who now lives locally,is helping those suffering from a painful ailment by bringing awareness to the New York stage.

Michael Kuluva is a fashion designer who has travelled the world and now calls Barrie home. Kuvula also lives with rheumatoid arthritis, but he doesnt let it define or hinder him. The autoimmune disorder primarily affects joints and can be very painful, something Kuvula knows all too well.

I was diagnosed 12 years ago and I didnt really know what to expect, the 37-year-old said. It has been a tough road at times, but you learn to live with and deal with all that it comes with.

Kuluva has even taken his passion for fashion design and used it to not only bring awareness to arthritis, but also help those who suffer from it.

The Newest Normal virtual event will premiereduring New York Fashion Week on Sept. 16 at 8 p.m. on the Virtual Fashion Show website and on YouTube.

Kuvula needed to film his show with models and a crew, but during COVID timesthat was tricky.

I was supposed to get back to the States, but obviously international travel couldnt happen. We filmed it here in downtown Barrie with local models and very few people in order to follow COVID protocol,Kuvula said. It was a very unique event and makes you realize that when you want to accomplish your goals, you can find a way.

Kuluva has been a part of New York Fashion Week for the last 11 seasons and will be a prominent figure in the 2020 edition. This years collection from the designer is titled Tumbler and Tipsy and includes clothes that are arthritis-friendly.

For people with arthritis, it is all about accessibility and comfort. Buttons are no good, so Ive altered that a bit with zippers, straps and other easy-to-wear items,Kuluva said. We know how to live with the discomfort, but we shouldn't have to let it stop us from getting out there and wearing what we want.

This years Kuluva collection is being described as deliberately sassy and also includes hand-painted, glow-in-the-dark details thoughtfully placed to emphasize where people living with arthritis experience pain.

It is fun, obviously, but it also highlights the pains that we experience that many dont know we have. Glowing over the joints and other spots that experience pain is a justa way to bring awareness to arthritis, said Kuluva.

Kuluva has travelled all over the world and in what he called, the different realms of New York, Los Angelesand Europe.

For the last four years, he has called Barrie home with his partner and enjoys everything about the region, even dedicating a line of clothes to it.

Barrie is wonderfuland the whole area is beautiful. Id obviously been to Toronto before and being in Barrie is even so close to Muskoka, said Kuluva. I have a Tipsy line of clothes for Muskoka, Toronto and the Canadian feel.

For more on Kuvula and his work, click here to see his website.

Read the original post:
Local fashion designer unveiling new line of arthritis-friendly clothing - OrilliaMatters